JP6663000B2 - 関節リウマチの診断のための自己抗原 - Google Patents

関節リウマチの診断のための自己抗原 Download PDF

Info

Publication number
JP6663000B2
JP6663000B2 JP2018511342A JP2018511342A JP6663000B2 JP 6663000 B2 JP6663000 B2 JP 6663000B2 JP 2018511342 A JP2018511342 A JP 2018511342A JP 2018511342 A JP2018511342 A JP 2018511342A JP 6663000 B2 JP6663000 B2 JP 6663000B2
Authority
JP
Japan
Prior art keywords
filamin
subject
sulfatase
acetylglucosamine
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018511342A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018517151A (ja
JP2018517151A5 (enExample
Inventor
アレン シー． スティア
アレン シー． スティア
エリース イー． ドルアン
エリース イー． ドルアン
Original Assignee
ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル
ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル, ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル filed Critical ザ ジェネラル ホスピタル コーポレーション ドゥーイング ビジネス アズ マサチューセッツ ジェネラル ホスピタル
Publication of JP2018517151A publication Critical patent/JP2018517151A/ja
Publication of JP2018517151A5 publication Critical patent/JP2018517151A5/ja
Application granted granted Critical
Publication of JP6663000B2 publication Critical patent/JP6663000B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018511342A 2015-05-12 2016-05-12 関節リウマチの診断のための自己抗原 Active JP6663000B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562160320P 2015-05-12 2015-05-12
US62/160,320 2015-05-12
US201562162295P 2015-05-15 2015-05-15
US62/162,295 2015-05-15
PCT/US2016/032077 WO2016183310A1 (en) 2015-05-12 2016-05-12 Autoantigens for diagnosis of rheumatoid arthritis

Publications (3)

Publication Number Publication Date
JP2018517151A JP2018517151A (ja) 2018-06-28
JP2018517151A5 JP2018517151A5 (enExample) 2019-06-13
JP6663000B2 true JP6663000B2 (ja) 2020-03-11

Family

ID=57248470

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018511342A Active JP6663000B2 (ja) 2015-05-12 2016-05-12 関節リウマチの診断のための自己抗原

Country Status (6)

Country Link
US (1) US10429379B2 (enExample)
EP (1) EP3294901B1 (enExample)
JP (1) JP6663000B2 (enExample)
AU (1) AU2016261939A1 (enExample)
CA (1) CA2985637A1 (enExample)
WO (1) WO2016183310A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3463441B1 (en) 2016-06-07 2023-10-25 The General Hospital Corporation Identification of a t cell epitope of prevotella copri that induces t cell responses in patients with rheumatoid arthritis
US20180280503A1 (en) 2017-04-04 2018-10-04 The Johns Hopkins University Anti-pad2 antibody for treating and evaluating rheumatoid arthritis
JP7202010B2 (ja) * 2017-07-06 2023-01-11 国立大学法人 筑波大学 関節リウマチ診断薬
WO2020083834A1 (en) * 2018-10-22 2020-04-30 F. Hoffmann-La Roche Ag Profiling of rheumatoid arthritis autoantibody repertoire and peptide classifiers therefor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1105734B (it) * 1977-07-14 1985-11-04 Syva Co Prova di legame di competizione di antienzima omogeneo
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
US5248595A (en) 1991-10-08 1993-09-28 Eastman Kodak Company Wash composition, test kit and method for determination of microorganisms associated with periodontal diseases
US5750356A (en) 1996-05-31 1998-05-12 Anergen, Inc. Method for monitoring T cell reactivity
AU2002230997A1 (en) 2000-12-15 2002-06-24 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
WO2003029277A2 (en) * 2001-10-03 2003-04-10 Rigel Pharmaceuticals, Inc. Modulators of lymphocyte activation and migration
US8198401B2 (en) * 2003-03-07 2012-06-12 London Health Sciences Centre Research Inc. Peptides associated with HLA-DR MHC class II molecule and involved in rheumatoid arthritis
EP1664796B1 (en) 2003-09-15 2010-12-15 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis
PT1882946E (pt) 2003-12-23 2010-04-21 Roche Diagnostics Gmbh Método para avaliar artrite reumatóide através da medição de anti-ccp e interleucina 6
EP1721162B1 (en) 2004-02-27 2008-09-24 Roche Diagnostics GmbH Method of assessing rheumatoid arthritis by measuring anti-ccp and serum amyloid a
EP1774328A1 (en) 2004-07-23 2007-04-18 Novartis AG Biomarkers for rheumatoid arthritis (ra)
US20070148704A1 (en) 2005-10-06 2007-06-28 Ursula Klause Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
CN102597268B (zh) * 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
WO2012040264A2 (en) * 2010-09-21 2012-03-29 The General Hospital Corporation Diagnostic tests for immune reactivity with human endothelial cell growth factor
ES2574790T3 (es) * 2011-07-01 2016-06-22 Inova Diagnostics, Inc. Procedimiento para aumentar la especificidad de pruebas de diagnóstico para enfermedades autoinmunitarias
CA3261641A1 (en) 2013-03-13 2025-06-12 Oncour Pharma, Inc. Immune-modifying particles for the treatment of inflammation
EP3463441B1 (en) * 2016-06-07 2023-10-25 The General Hospital Corporation Identification of a t cell epitope of prevotella copri that induces t cell responses in patients with rheumatoid arthritis

Also Published As

Publication number Publication date
JP2018517151A (ja) 2018-06-28
EP3294901B1 (en) 2023-05-03
EP3294901A1 (en) 2018-03-21
US10429379B2 (en) 2019-10-01
AU2016261939A1 (en) 2018-01-04
WO2016183310A1 (en) 2016-11-17
US20180156778A1 (en) 2018-06-07
EP3294901A4 (en) 2018-11-21
CA2985637A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
Matsumoto et al. Low prevalence of antibodies to glucose‐6‐phosphate isomerase in patients with rheumatoid arthritis and a spectrum of other chronic autoimmune disorders
van Beers et al. Anti-citrullinated fibronectin antibodies in rheumatoid arthritis are associated with human leukocyte antigen-DRB1 shared epitope alleles
JP5555846B2 (ja) 急性中枢神経障害の予後判定方法
JP5998318B2 (ja) 新規血管炎の検査方法および検査用試薬
JP6543332B2 (ja) 関節リウマチの血清学的な診断方法
JP6663000B2 (ja) 関節リウマチの診断のための自己抗原
EP3415909B1 (en) Diagnosis of a neuroautoimmune disease
Clement et al. Autoimmune response to transthyretin in juvenile idiopathic arthritis
US20230039907A1 (en) Assessing and treating autoimmune ataxia
Katsumata et al. Identification of three new autoantibodies associated with systemic lupus erythematosus using two proteomic approaches
WO2012156313A1 (en) Method for the diagnosis of early rheumatoid arthritis
Melkersson et al. Increased antibody reactivity against insulin receptor-A and insulin like growth factor 1 receptor and their ligands in cerebrospinal fluid and serum of patients with schizophrenia or related psychosis
US9335329B2 (en) Diagnostic prediction of rheumatoid arthritis and systemic lupus erythematosus
WO2016003719A1 (en) Autoantigens for diagnosis of chronic inflammatory diseases
Park et al. Evaluation of a specific diagnostic marker for rheumatoid arthritis based on cyclic citrullinated peptide
DK2671084T3 (en) Biomarkers for osteoarthritis
US20130302329A1 (en) Diagnostic tests for immune reactivity with human endothelial cell growth factor
US20180313830A1 (en) Peptide and biomarker associated with inflammatory disorders, and uses thereof
WO2018024732A1 (en) Diagnosis and therapy of ankylosing spondylitis
JP2012224594A (ja) 環状シトルリン化グルコース−６−リン酸イソメラーゼペプチドおよび関節リウマチ症診断方法
Mahler et al. Research article Clinical and serological evaluation of a novel CENP-A peptide based ELISA
Martín et al. CONTRIBUTION OF BRONCHOALVEOLAR LAVAGE TO THE DIAGNOSIS OF DIFFUSE INTERSTITIAL LUNG DISEASES
JP2021028573A (ja) 筋疾患の診断のためのバイオマーカー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171206

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200213

R150 Certificate of patent or registration of utility model

Ref document number: 6663000

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250